The report on Global Urticaria Drug Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition []
No summary available.
Taro Pharmaceutical Industries (NYSE:TARO) released its quarterly earnings data on Wednesday. The company reported $0.86 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.01 by ($0.15), MarketWatch Earnings reports. Taro Pharmaceutical Industries had a positive return on equity of 10.36% and a negative net margin of 45.94%. Taro Pharmaceutical Industries […]
Stay up-to-date and exploit latest trends of Nasal Polyps Treatment Market with latest edition released by AMA. Nasal Polyps Treatment Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Nasal Polyps Treatment
Taro Pharmaceutical Industries announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Taro Pharmaceutical Industries announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Taro Pharmaceutical Industries Ltd. (NYSE:TARO)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $63.93 and traded as low as $58.47. Taro Pharmaceutical Industries shares last traded at $58.47, with a volume of 28,440 shares. Several brokerages recently issued reports on TARO. ValuEngine […]
NEW DELHI: Hurt by one-time loss, leading drugmaker Sun Pharma reported a surprising loss during the June quarter while sales declined in all regions of the world the company operates in.However, the management hailed the company's performance. They said it has done well given the challenges it faced and managed to hold its market share in India and the US.How much did the company earn?Sun Pharma reported a loss of Rs 1,655.60 crore in the quarter, sharply lower from the expectation as it recognised an exceptional item. The company’s revenues from operations also fell to Rs 7,467.19 crore, from Rs 8,259.30 crore a year ago. EBITDA was at Rs 1,725 crores, with resulting EBITDA margin of 23.1 per cent.What is that exceptional item?The company reported a one-time loss of Rs 3,633.33 crore as it provided for settlement of legal cases involving two subsidiaries Taro Pharmaceuticals and Dusa Pharmaceuticals with the US government’s Department of Justice.What regions contributed the most to revenue?Company’s India sales were at Rs 2,388 crore, growing 3.2 per cent over the corresponding quarter last year.
Sun Pharmaceutical Industries has announced that one of the fully-owned subsidiaries of Taro Pharmaceutical Industries Ltd is about to to acquire Aquinox Pharmaceuticals (Canada) Inc for $8.2 milli…
Sun Pharmaceutical Industries on Wednesday said that a wholly-owned subsidiary of Taro Pharmaceutical Industries Ltd will acquire Aquinox Pharmaceuticals (Canada) Inc for $8.2 million.
On Wednesday, in a stock exchange filing, Sun Pharma said that a subsidiary of its American arm Taro Pharmaceutical will acquire Canada's Aquinox Pharmaceutical for $8.2 million (approx Rs 61.35 crore) in cash. Aquinox Pharmaceuticals is a corporation organised
Drug major Sun Pharma on Wednesday said a subsidiary of its American arm Taro Pharmaceutical will acquire Canada's Aquinox Pharmaceutical for USD 8.2 million (approx Rs 61.35 crore) in cash. 100 per cent shareholding, constituting equity shares and non-voting preferred shares, will be acquired, it said. A cash consideration of USD 8.2 million will be paid for acquisition of all shares of Aquinox Pharmaceutical, Sun Pharma said.
Sun Pharma stock trades higher than 20, 50, 100 and 200-day but lower than 5-day moving averages. Sun Pharma shares have risen 0.21% in one month and 12% since the beginning of the year 2020
New Delhi: Sun Pharma on Friday said its American arm Taro Pharmaceutical has resolved all cases involving multi-year investigations by US Department of Justice into the country's generic pharmaceutical industry. The US Department of Justice (DOJ) had launched investigations against the company over generic drug pricing. "Taro Pharmaceuticals USA, Inc, has resolved all cases involving the company in connection with the multi-year investigations by the DOJ, Antitrust Division and Civil Division, into the US generic pharmaceutical industry," Sun Pharma said in a regulatory filing. Under a deferred prosecution agreement reached with the DOJ, it said, adding that the department will file an information for conduct that took place between 2013 and 2015. Taro Pharmaceutical said, if the company adheres to the terms of the agreement, including the payment of USD 205.7 million (approx Rs 1,542 crore), the DOJ will dismiss the information at the end of a three-year period. "The company has also reached a framework understanding with the DOJ Civil Division, subject to final agreement and agency authorisation, in which the company has agreed to pay USD 213.3 million (approx Rs 1,599 crore) to resolve all claims related to federal healthcare programs," it added.
On Friday, shares of Sun Pharmaceutical Industries Limited rose 4 percent to Rs 497.80 in early trade after its US subsidiary, Taro Pharma reached a settlement agreement with the US Department of Justice (DoJ), Antitrust and Civil divisions to pay $205.7
- ← Atrás
- 1
- 2
- 3
- Siguiente →